https://orcid.org/0000-0002-2603-2305
References
- Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa140647025671254
- Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4–5. doi:10.1016/s1470-2045(15)00543-426758760
- Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/s0140-6736(18)30207-129433850
- Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–718. doi:10.1016/s1470-2045(19)30020-830922731
- Balmelli C, Railic N, Siano M, et al. Lenvatinib in advanced radioiodine-refractory thyroid cancer - a retrospective analysis of the swiss lenvatinib named patient program. J Cancer. 2018;9(2):250–255. doi:10.7150/jca.2231829344270
- Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111. doi:10.1136/gutjnl-2012-30277923100216
- Kawakami H, Kubota Y, Ban T, Shibata N, Hosokawa A. Lenvatinib-induced acute pancreatitis associated with a pancreatic pseudocyst and splenic pseudoaneurysms. Pancreas. 2018;47(6):e34–e35. doi:10.1097/mpa.000000000000106129894425
- Hundahl SA, Cady B, Cunningham MP; U.S. and German Thyroid Cancer Study Group, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996: an American college of surgeons commission on cancer patient care evaluation study. Cancer. 2000;89(1):202–217.10897019
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.002026462967
- Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37(1):93–99. doi:10.1016/j.ejso.2010.10.01021093207
- St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146(3):1145–1153. doi:10.1210/en.2004-113415564323
- Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3–16. doi:10.1385/ep:13:1:0312114746
- He G, Zhao B, Zhang X, Gong R. Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett. 2014;7(2):439–443. doi:10.3892/ol.2013.171324396464
- Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94(12):4735–4741. doi:10.1210/jc.2009-123319837916
- Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. doi:10.1016/s0140-6736(14)60421-924768112
- Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet. 2015;386(9988):85–96. doi:10.1016/s0140-6736(14)60649-825616312
- Shelton C, LaRusch J, Whitcomb DC, et al. Pancreatitis overview In: Adam MP, Ardinger HH, Pagon RA, editors. Genereviews(®). Seattle: University of Washington, Seattle Copyright © 1993–2020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
- Spanier BW, Tuynman HA, van der Hulst RW, Dijkgraaf MG, Bruno MJ. Acute pancreatitis and concomitant use of pancreatitis-associated drugs. Am J Gastroenterol. 2011;106(12):2183–2188. doi:10.1038/ajg.2011.30321912439
- Ghatalia P, Morgan CJ, Choueiri TK, Rocha P, Naik G, Sonpavde G. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94(1):136–145. doi:10.1016/j.critrevonc.2014.11.00825541349
- Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. Jop. 2010;11(3):291–293.20442535
- Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J. 2007;100(9):909–911.17902294